FindTrial
Sign In

Efficacy and Patient’s Preference for Fexuprazan On-Demand Therapy in Gastroesophageal Reflux Disease

Efficacy and Patient’s Preference for Fexuprazan On-Demand Therapy in Gastroesophageal Reflux Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008526
Enrollment
32
Registered
2023-06-16
Start date
2022-08-11
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Hanyang University Guri Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with typical symptoms for gastroesophageal reflux disease Patients with erosive esophagitis diagnosed with previous endoscopic examination

Exclusion criteria

Exclusion criteria: Patients who underwent esophageal, gastric, or duodenal surgery Previous history of sensitivity for fexuprazan

Design outcomes

Primary

MeasureTime frame
The proportion of patients who favored on-demand therapy—

Secondary

MeasureTime frame
GERD-Q (heartburn, regurgitation) score;PAGI-SYM score—

Countries

Korea, Republic of

Contacts

Public ContactChan Hyuk Park

Hanyang University Guri Hospital

yesable7@hanmail.net+82-31-560-2230

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026